NASDAQ:EXEL - Exelixis Stock Price, Forecast & News

Exelixis trades on the NASDAQ under the ticker symbol "EXEL."

Exelixis, Inc. (NASDAQ:EXEL) announced its quarterly earnings results on Wednesday, October, 30th. The biotechnology company reported $0.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.19 by $0.12. The biotechnology company had revenue of $271.70 million for the quarter, compared to analysts' expectations of $228.17 million. Exelixis had a net margin of 64.05% and a return on equity of 25.55%. Exelixis's quarterly revenue was up 20.5% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.44 earnings per share. View Exelixis' Earnings History.

Exelixis is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for Exelixis.

11 brokers have issued 12-month price targets for Exelixis' stock. Their forecasts range from $19.00 to $35.00. On average, they expect Exelixis' stock price to reach $26.50 in the next twelve months. This suggests a possible upside of 33.7% from the stock's current price. View Analyst Price Targets for Exelixis.

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Exelixis in the last year. There are currently 3 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Exelixis.

Media stories about EXEL stock have been trending positive on Monday, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Exelixis earned a media sentiment score of 3.0 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for Exelixis.

Exelixis saw a increase in short interest during the month of December. As of December 31st, there was short interest totalling 18,100,000 shares, an increase of 17.0% from the December 15th total of 15,470,000 shares. Based on an average daily volume of 2,910,000 shares, the days-to-cover ratio is currently 6.2 days. Approximately 6.2% of the shares of the stock are short sold. View Exelixis' Current Options Chain.

Some companies that are related to Exelixis include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Repligen (RGEN).

Based on aggregate information from My MarketBeat watchlists, some companies that other Exelixis investors own include Micron Technology (MU), NVIDIA (NVDA), Advanced Micro Devices (AMD), Alibaba Group (BABA), Gilead Sciences (GILD), Incyte (INCY), Intel (INTC), BioMarin Pharmaceutical (BMRN), Corbus Pharmaceuticals (CRBP) and Puma Biotechnology (PBYI).

Exelixis' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Chicago Capital LLC (0.27%), Tealwood Asset Management Inc. (0.04%), Louisiana State Employees Retirement System (0.02%), Assenagon Asset Management S.A. (0.02%), State of Alaska Department of Revenue (0.02%) and Alpine Global Management LLC (0.00%). Company insiders that own Exelixis stock include Alan M Garber, Carl B Feldbaum, Charles Cohen, Christopher J Senner, George A Scangos, George Poste, Gisela Schwab, Jeffrey Hessekiel, Lance Willsey, Michael Morrissey, Patrick J Haley, Peter Lamb, Stelios Papadopoulos and Vincent T Marchesi. View Institutional Ownership Trends for Exelixis.

EXEL stock was sold by a variety of institutional investors in the last quarter, including Tealwood Asset Management Inc., State of Alaska Department of Revenue and Sonora Investment Management LLC. Company insiders that have sold Exelixis company stock in the last year include Alan M Garber, Carl B Feldbaum, Charles Cohen, Christopher J Senner, George A Scangos, George Poste, Gisela Schwab, Jeffrey Hessekiel, Lance Willsey, Michael Morrissey, Patrick J Haley, Peter Lamb and Vincent T Marchesi. View Insider Buying and Selling for Exelixis.

EXEL stock was bought by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Alpine Global Management LLC, Chicago Capital LLC, Nisa Investment Advisors LLC, Huntington National Bank, Manchester Financial Inc. and Louisiana State Employees Retirement System. View Insider Buying and Selling for Exelixis.

Shares of EXEL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of EXEL stock can currently be purchased for approximately $19.82.

Exelixis has a market capitalization of $6.02 billion and generates $853.83 million in revenue each year. The biotechnology company earns $690.07 million in net income (profit) each year or $1.43 on an earnings per share basis. Exelixis employs 484 workers across the globe.View Additional Information About Exelixis.

The official website for Exelixis is http://www.exelixis.com/.

Exelixis' mailing address is 1851 Harbor Bay Parkway, Alameda CA, 94502. The biotechnology company can be reached via phone at 650-837-7000 or via email at [email protected]